SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/21/24 Protagenic Therapeutics, Inc./New 8-K:7,8,9 3/19/24 12:268K M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 48K 2: EX-99.1 Miscellaneous Exhibit HTML 11K 7: R1 Cover HTML 48K 9: XML IDEA XML File -- Filing Summary XML 13K 12: XML XBRL Instance -- form8-k_htm XML 21K 8: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 4: EX-101.DEF XBRL Definitions -- ptix-20240319_def XML 73K 5: EX-101.LAB XBRL Labels -- ptix-20240319_lab XML 103K 6: EX-101.PRE XBRL Presentations -- ptix-20240319_pre XML 70K 3: EX-101.SCH XBRL Schema -- ptix-20240319 XSD 14K 10: JSON XBRL Instance as JSON Data -- MetaLinks 27± 36K 11: ZIP XBRL Zipped Folder -- 0001493152-24-010741-xbrl Zip 22K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): i March 19, 2024
(Exact name of Company as specified in its charter)
i Delaware | i 001-12555 | i 06-1390025 | ||
(State
or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
i 149 Fifth Avenue, i Suite 500, i New York, i NY | i 10010 | |
(Address of principal executive offices) | (Zip Code) |
(Company’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Item 7.01 Regulation FD Disclosure.
On March 21, 2024, the Company issued a press release announcing resolution of the Company’s outstanding Nasdaq deficiency notice. A copy of the press release is furnished with this report as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1 attached hereto, shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly stated by specific reference in such a filing.
Item 8.01 Other Events.
On March 19, 2024, the Company received written notice from the Nasdaq Listing Qualifications Department (the “Staff”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) by maintaining a minimum closing bid price of the Company’s common stock of at least $1.00 per share for the last ten consecutive trading days, from March 5, 2024 to March 18, 2024, and that this matter is now closed. As previously reported, on November 21, 2023, Nasdaq notified the Company that, the closing bid price for the Company’s common stock had been below the minimum $1.00 per share requirement for 30-consecutive business in violation of the Minimum Bid Price Requirement.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. |
Description | |
99.1 | Press release - “Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice” | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROTAGENIC THERAPEUTICS, INC. | ||
Date: March 21, 2024 | By: | /s/ Alexander K. Arrow |
Name: | Alexander K. Arrow | |
Title: | Chief Financial Officer |
3 |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 3/21/24 | |||
For Period end: | 3/19/24 | |||
3/18/24 | ||||
3/5/24 | ||||
11/21/23 | 8-K | |||
List all Filings |